Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

108 results about "Immunodeficient Mouse" patented technology

Any mouse strain with a faulty immune system such that its ability to fight infectious disease is compromised or ablated. Immunodeficient mice may be derived by inbreeding or genetic engineering. Immunodeficiency may also be induced by some chemicals, heavy metals, alkylating agents, radiation, and thymectomy.

Circulating tumor cell mouse model and construction method and application thereof

The invention relates to a circulating tumor cell mouse model and a construction method and application thereof. The method includes the following steps of 1, subcutaneous transplantation, wherein a primary tumor tissue sample is transplanted into the body of an immunodeficient mouse to construct a primary cancer heterotransplantation model PDX; 2, collection of circulating tumor cells, wherein the circulating tumor cells in peripheral blood in the primary cancer heterotransplantation model obtained in the step 1 are collected; 3, renal sac membrane transplantation, wherein the circulating tumor cells collected in the step 2 are transplanted into the renal sac membrane of the immunodeficient mouse, and then the circulating tumor cell mouse model is successfully constructed. According to the method, the mode of transplantation with two or more times of passages is adopted, the CTCs in the primary cancer heterotransplantation model are transplanted into the body of the immunodeficient mouse through renal sac membrane, and the circulating tumor cell mouse model is obtained; the circulating tumor cell mouse model can be applied to research on the in-vivo metastasis mechanism and proliferation condition of CTCs.
Owner:湖南昭泰生物医药有限公司

Targeting metabolic enzymes in human cancer

Targeting metabolic enzymes in human cancer Abstract Lung cancer is a devastating disease and a major therapeutic burden with poor prognosis. The functional heterogeneity of lung cancer (different tumor formation ability in bulk of tumor) is highly related with clinical chemoresistance and relapse. Here we find that, glycine dehydrogenase (GLDC), one of the metabolic enzyme involved in glycine metabolism, is overexpressed in various subtypes of human lung cancer and possibly several other types of cancers. GLDC was found to be highly expressed in tumor-initiating subpopulation of human lung cancer cells compared with non-tumorigenic subpopulation. By array studies we showed that normal lung cells express low levels of GLDC compared to xenograft and primary tumor. Functional studies showed that RNAi inhibition of GLDC inhibits significantly the clonal growth of tumor-initiating cells in vitro and tumor formation in immunodeficient mice. Overexpression of GLDC in non-tumorigenic subpopulation convert the cells to become tumorigenic. Furthermore, over-expression of GLDC in NIH / 3T3 cells and human primary lung fibroblasts can transform these cells, displaying anchorage-independent growth in soft agar and tumor-forming in mice. Not only is GLDC is expressed human lung cancer, it is also up-regulated in other types of cancer, such as colon cancer. RNAi knockdown of GLDC in colon cancer cell line, CACO-2 cells, can also inhibit the tumor formation in mice. Thus GLDC maybe a new metabolic target for treatment of lung cancer, and other cancers.
Owner:AGENCY FOR SCI TECH & RES

Cervices intraepithelial neoplasia model and model establishing method

InactiveCN101125102ARich sourcesExplore the mechanism of carcinogenesisDiagnosticsSurgeryHuman tumorImmunodeficiency
The present invention relates to a cervical intraepithelial neoplasia model and the method of establishing model, which is characterized in that the cervical intraepithelial neoplasia tissue is embedded in the immunodeficiency mice to establish cervical intraepithelial neoplasia model. The method of establishing model is characterized in that the cervical intraepithelial neoplasia tissue is respectively taken from the biopsy under the vaginoscope and the tissues which are confirmed by the department of pathology and is inoculated subcutaneously in the back of the mice; the immunodeficiency mice of the present invention can overcome the xenoislet immune rejection reaction and receive the transplantation of the human tumor tissues, the tissue model after the transplantation has significant and stable character, short observation period and greater clinical reference significance of the experimental results. The present invention can explore the mechanism of the carcinogenesis of cervical carcinoma by outcome of the pathological process of CIN I, CIN II and CIN III animal models. Furthermore, by observing the period of the outcome of the cervical intraepithelial neoplasia tissue of the animal model, the present invention provides the feasible clinical animal experimental model for reversing the malignant transformation of the CIN I and CIN II lesion tissues.
Owner:ANHUI PROVINCIAL HOSPITAL

Method for reconstitution of hair follicle in vivo

Relating to the technical field of aesthetic and plastic surgery, the invention discloses a method for reconstitution of hair follicle in vivo. The method includes the steps of: firstly performing cell separation, culturing and amplifying freshly isolated cells, and using cell spheres or cell lumps for culture, conducting cell preparation before transplantation, directly taking freshly isolated skin single cells, or cultured and amplified epidermal and dermal cells mixed in proportion, or cell spheres or cell lumps, and resuspending them in a culture solution, narcotizing an immunodeficient mouse, using a syringe needle or cutisector to pierce a hole on the skin of the naked mouse, using a pipette gun head to transfer the well prepared cell suspension into the pierced hole, after transferring all the cells, performing covering with a silica gel membrane and conducting suturing, then laying a layer of vaseline gauze, conducting bandaging and timely observation and treatment, thus finding hair growth 3 weeks later. The method provided by the invention has the characteristics of simple operation, small trauma, high hair follicle formation efficiency, and large injectable cell number range, is suitable for injection of clump cells and a large number of cells, and is suitable for development and application in clinical practice or cosmetic medicine for treatment of hair loss diseases.
Owner:山东省口腔医院

Method for constructing ovarian cancer transplantation tumor model based on organoid method and application of method

The invention discloses a method for constructing an ovarian cancer transplantation tumor model based on an organoid method, and belongs to the field of medicines. According to the invention, an "organoid" culture technology is adopted, and a micro-carrier is used as a support material for culturing a patient-derived ovarian cancer cell-3D material complex; then the cell-3D material complex is directly inoculated under the skin of a normal immune mouse, and a patient-derived ovarian cancer transplantation tumor model is constructed, so that a problem that immune-deficiency mice such as severecombined immunodeficiency (SCID) mice, nude mice and the like are adopted in existing human ovarian cancer transplantation tumor models, the price is high, breeding is difficult, the tumor forming rate is low and the like can be solved, especially a problem that the existing immune-deficiency mouse human ovarian cancer transplantation tumor model cannot reflect impotent effects of an organism immune system in occurrence and development processes of tumors is solved, and a problem that an immune-deficiency mouse human transplantation tumor model is long in tumor forming period and cannot meet drug allergy requirements of patients urgently needing clinic drug therapy is solved. The method is applied to the field of mouse model construction.
Owner:上海美峰生物技术有限公司

Expression plasmid adjuvant for enhancing chemotherapeutic effect of tumor chemotherapeutics and preparation method thereof

The invention relates to the field of biomedicine. 5-fluorouracil (5-FU) is widely applied to the chemotherapy of gastral malignant tumors, but primary and acquired medicament resistant phenomena in the chemotherapy of colon cancer are universal; cell apoptosis is an important approach that chemotherapeutics play a role, and APAF-1 serving as regulatory protein is mainly involved in signal transduction of a mitochondrion approach of apoptosis; miR-23a can be combined with APAF1 serving as a target gene thereof so as to reduce the expression of the APAF1, and the apoptosis caused by the mitochondrion approach due to the chemotherapy is reduced so as to enhance the tolerance of the tumors to the chemotherapeutics; and the number of apoptotic cells is increased by reducing the expression amount of the in-vivo miR-23a so as to enhance the sensibility of the chemotherapeutics. The invention provides a PLKO-anti-miR-23a vaccine adjuvant for enhancing the chemotherapeutic effect of the chemotherapeutics, particularly the 5-FU. In-vitro experiments prove that the vaccine adjuvant can enhance the apoptosis level of colon cancer cells caused by the 5-FU serving as the chemotherapeutics obviously, and in-vivo experiments show that the vaccine adjuvant can enhance the chemotherapeutic effect of the 5-FU obviously, inhibit tumor growth and prolong the survival period of immunodeficient mice.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY

Method for constructing a patient-derived tumor xenograft model in mice immunized with hepatocellular carcinoma based on organ-like method, and application thereof

The invention belongs to the field of medicine, and relates to a method for constructing a patient-derived tumor xenograft model in mice immunized with hepatocellular carcinoma based on an organ-likemethod, and an application thereof. The aim of the invention is to use the organ-like culture technology, adopts microcarrier as scaffold material, and combines the liver cancer cells from patient toculture the cells. The invention also discloses an organ-like method for preparing the liver cancer cells-3D material complex, and then directly into that cell-3D material complex is inoculated subcutaneously into normal immunized mice to construct liver cancer transplanted tumor model from patients in vivo, which solved the problems of using nude mice, SCID mice and other immunodeficient mice, which are difficult to feed, expensive and lower tumor formation rate. Especially, it can solve the problem that human hepatocellular carcinoma transplanted tumor model in immunodeficiency mice can notreflect the important role of immune system in tumor occurrence and development, and human tumor transplanted tumor model in immunodeficiency mice has a long tumor formation cycle, which urgently needs the drug-sensitive demand of patients with clinical urgent need. The invention is applied to the field of mouse model construction.
Owner:上海美峰生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products